OMDA News & Events

Omada Health announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol, yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level. This gap underscores a core challenge in traditional care models that are not designed to sustain the day-to-day behaviors required to improve cholesterol numbers over time. "Launching with a market-leading employer is a signal that there is a need for between-visit cholesterol care that properly addresses long-term cardiovascular risk in their populations," said Sean Duffy, CEO & Co-Founder of Omada Health. "Because of our flexible infrastructure, we were able to quickly add cholesterol support on our existing platform, giving customers one partner for integrated cardiometabolic care in response to their demand."

Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be between $72 million and $74 million, representing an increase of 50% to 54% over the fourth quarter of 2024. "Our preliminary 2025 results underscore the growing relevance of our between-visit care model as both buyers and members seek new solutions," said Sean Duffy, Omada's Co-founder and CEO. "During the year, we enhanced our GLP-1 care offerings and advanced the use of AI across our platform with an aim to drive sustainable member outcomes and support customers navigating evolving cost and care dynamics."